Eyevance Pharmaceuticals Revenue and Competitors

Dallas, TX USA

Location

$30M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Eyevance Pharmaceuticals's estimated annual revenue is currently $5.1M per year.(i)
  • Eyevance Pharmaceuticals's estimated revenue per employee is $100,500
  • Eyevance Pharmaceuticals's total funding is $30M.

Employee Data

  • Eyevance Pharmaceuticals has 51 Employees.(i)
  • Eyevance Pharmaceuticals grew their employee count by -40% last year.

Eyevance Pharmaceuticals's People

NameTitleEmail/Phone
1
VP, Market Access and Trade ChannelsReveal Email/Phone
2
AP/AR LeadReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$32.4M16120%N/AN/A
#2
$16.3M817%N/AN/A
#3
$18.7M9316%N/AN/A
#4
$62.5M0N/AN/AN/A
#5
$12.3M617%N/AN/A
#6
$3.2MN/A$22.2MN/A
#7
$184.1M91638%$50MN/A
#8
$27.7M1388%N/AN/A
#9
$112.4M5598%N/AN/A
#10
$12.5M6211%N/AN/A
Add Company

What Is Eyevance Pharmaceuticals?

EYEVANCE Pharmaceuticalsᅢᄁ¬ツᆲ¬トᄁ mission is to develop and commercialize INNOVATIVE and IMPACTFUL ophthalmic products to enable optimal vision and better quality of life for all patients

keywords:N/A

$30M

Total Funding

51

Number of Employees

$5.1M

Revenue (est)

-40%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Eyevance Pharmaceuticals News

2022-04-20 - Combination eye drop manages inflammation and infection ...

... anti-inflammatory and lubricant (Tobradex ST ophthalmic suspension, Eyevance Pharmaceuticals) managed inflammation and infection,...

2022-04-06 - Perioperative dry eye treatment necessary for best postop ...

... Sun Pharmaceutical) or Xiidra (lifitegrast ophthalmic solution 5%, Novartis). ... acetate as found in Flarex (Eyevance Pharmaceuticals).

2022-04-06 - Nicox's NCX 470 Dolomites Phase 2 Results Published in ...

... in multiple geographies, including to Eyevance Pharmaceuticals, LLC, ... of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.5M5121%N/A
#2
$14.7M5111%N/A
#3
$15.1M5121%N/A
#4
$7.3M51-38%N/A
#5
$13.6M5218%N/A